MS Therapy Archive - Page 4 of 5

… and what about secondary progressive Multiple Sclerosis?

12. March 2018 Prof. Dr. med. Mathias Mäurer General, MS Therapy

However, this is a very valid question. Because in contrast to the “relatively” rare primary progressive MS (PPMS), most people with MS with a chronic progressive course belong to the group of secondary progressive MS.

Gilenya – Lymphocyte Levels in Clinical Practice

22. September 2017 Prof. Dr. med. Mathias Mäurer General, MS Therapy

Lymphocyte levels also play an important role in monitoring the active substance Fingolimod (Gilenya). However, the considerations here are quite different from those for Dimethyl fumarate (Tecfidera – Lymphocyte levels in clinical practice from March

Cladribin – a new option for relapsing MS

28. August 2017 Prof. Dr. med. Mathias Mäurer General, MS Therapy

On August 25, 2017, the European Medicines Commission EMA approved the active ingredient Cladribin under the trade name MAVENCLAD® for the treatment of relapsing multiple sclerosis (MS) in patients with high disease activity.

Ein Arzt erklärt einem MS-Patienten am Bildschirm MRT-Bilder des Gehirns.

News from the AAN 2017

19. May 2017 Prof. Dr. med. Mathias Mäurer General, MS Therapy

As a rule, I try to report on international congresses within the framework of DocBlog, which are particularly relevant for MS patients. Without a doubt, this includes the meeting of the American Academy of Neurology

Intrathecal Cortisone Therapy

5. September 2016 Prof. Dr. med. Mathias Mäurer MS Therapy, Therapy for MS

Cortisone is used in the treatment of acute MS relapses in Multiple Sclerosis. Usually, a high-dose cortisone preparation is administered intravenously over a period of 3 to 5 days. In addition, high-dose intravenous cortisone administration

zwei runde, weiße Tabletten vor weißem Hintergrund

Lymphocytopenia under Tecfidera

27. May 2016 Prof. Dr. med. Mathias Mäurer MS Therapy

Dimethyl fumarate (Tecfidera®) has established itself as a first-line therapy for the treatment of multiple sclerosis. The availability of an effective oral therapy with a favorable side effect profile has expanded the possibilities of MS

Pregnancy under Tysabri therapy – how should one proceed?

5. February 2016 Prof. Dr. med. Mathias Mäurer General, MS Therapy

I had already written about the topic of pregnancy in women with mild/moderate MS in the context of this blog. In doing so, I had excluded women with highly active MS – so explicitly also

Sleep Disorders in MS

7. October 2015 Prof. Dr. med. Mathias Mäurer MS Symptoms, MS Therapy

The sleep of MS patients is rather less discussed in practice – although sleep disorders are a problem not to be underestimated and are probably more common than is generally assumed. Therefore, I would like

Pharmacological Therapy of Spasticity

18. September 2015 Prof. Dr. med. Mathias Mäurer MS Symptoms, MS Therapy

Spasticity is a symptom many MS patients suffer from. But what is spasticity exactly? It is not so easy to explain in a few words: Spasticity results from the disinhibition of reflex arcs due to

MS and Pregnancy – Recommendations for Mild/Moderate MS

10. September 2015 Prof. Dr. med. Mathias Mäurer General, MS Therapy

MS often affects young women, so the topic of pregnancy is interesting in many ways. One might think that many basic things are clear and one is primarily confronted with very specific questions. Surprisingly, however,

Category: MS Therapy

… and what about secondary progressive Multiple Sclerosis?

Gilenya – Lymphocyte Levels in Clinical Practice

Cladribin – a new option for relapsing MS

News from the AAN 2017

Intrathecal Cortisone Therapy

Lymphocytopenia under Tecfidera

Pregnancy under Tysabri therapy – how should one proceed?

Sleep Disorders in MS

Pharmacological Therapy of Spasticity

MS and Pregnancy – Recommendations for Mild/Moderate MS

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community